Assessment of MGP gene expression in cancer and contribution to prognosis

Biochimie. 2023 Nov;214(Pt B):49-60. doi: 10.1016/j.biochi.2023.06.004. Epub 2023 Jun 10.

Abstract

Matrix Gla protein (MGP) was first identified as a calcification physiological inhibitor and the causal agent of the Keutel syndrome. MGP has been suggested to play a role in development, cell differentiation, and tumorigenesis. This study aimed to compare MGP expression and methylation status in different tumors and adjacent tissues, using The Cancer Genome Atlas (TCGA) data repository. We investigated if changes in MGP mRNA expression were correlated to cancer progression and whether the correlation coefficients could be used for prognosis. Strong correlations were observed between altered MGP levels and disease progression in breast, kidney, liver, and thyroid cancers, suggesting that it could be used to complement current clinical biomarker assays, for early cancer diagnosis. We have also analyzed MGP methylation and identified CpG sites in its promoter and first intron with clear differences in methylation status between healthy and tumoral tissue providing evidence for epigenetic regulation of MGP transcription. Furthermore, we demonstrate that these alterations correlate with the overall survival of the patients suggesting that its assessment can serve as an independent prognostic indicator of patients' survival.

Keywords: Epigenetics; Gene expression; Matrix gla protein; Methylation; The cancer genome atlas.

MeSH terms

  • Cartilage Diseases*
  • Epigenesis, Genetic
  • Gene Expression
  • Humans
  • Matrix Gla Protein
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics
  • Prognosis